Free Pre-Market Technical Recap on Hologic and Three Additional Medical Supplies Stocks
Stock Research Monitor: BDX, EKSO, and HAE
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on HOLX sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Becton, Dickinson and Co. (NYSE: BDX), Ekso Bionics Holdings Inc. (NASDAQ: EKSO), Haemonetics Corp. (NYSE: HAE), and Hologic Inc. (NASDAQ: HOLX). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Becton, Dickinson and Co.
On Tuesday, shares in Franklin Lakes, New Jersey-based Becton, Dickinson and Co. recorded a trading volume of 985,634 shares. The stock ended at $244.55, declining 0.04% from the last trading session. The Company's shares have gained 23.82% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 6.12% and 10.20%, respectively. Furthermore, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have a Relative Strength Index (RSI) of 69.25.
On June 21st, 2018, research firm JP Morgan upgraded the Company's stock rating from ‘Overweight' to ‘Neutral'. Get the full research report on BDX for free by clicking below at:
www.wallstequities.com/registration/?symbol=BDX
Ekso Bionics Holdings
Richmond, California headquartered Ekso Bionics Holdings Inc.'s stock finished yesterday's session 9.28% lower at $1.76. A total volume of 506.860 shares was traded, which was above their three months average volume of 342.70 thousand shares. The Company's shares have gained 14.29% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.14% and 3.12%, respectively. Furthermore, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America and EMEA region, have an RSI of 49.60. To experience our free membership services anytime/ anywhere and access the free report on EKSO, click to register at:
www.wallstequities.com/registration/?symbol=EKSO
Haemonetics
At the close of trading on Tuesday, shares in Braintree, Massachusetts headquartered Haemonetics Corp. saw a rise of 0.23%, ending the day at $93.02. The stock recorded a trading volume of 776,874 shares, which was higher than its three months average volume of 705.60 thousand shares. The Company's shares have advanced 27.06% in the previous three months and 139.68% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 4.47% and 36.11%, respectively. Moreover, shares of Haemonetics, which provides hematology products and solutions, have an RSI of 55.73. Join our big investor community at Wall St. Equities today and get your free report on HAE at:
www.wallstequities.com/registration/?symbol=HAE
Hologic
Marlborough, Massachusetts headquartered Hologic Inc.'s shares ended the day 0.34% higher at $41.36 with a total trading volume of 1.12 million shares. The stock has gained 11.75% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 6.22% and 4.69%, respectively. Additionally, shares of Hologic, which develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the US, Europe, Asia/Pacific, and internationally, have an RSI of 68.75. Know more about HOLX in our free research coverage at:
www.wallstequities.com/registration/?symbol=HOLX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
